Research: Cancer gene inhibition shows step toward beating neuroblastomas
Neuroblastoma is a devastating solid tumor of childhood and emerges in the sympathetic nervous system while many kids who develop it are still toddlers.
Neuroblastoma is a devastating solid tumor of childhood and emerges in the sympathetic nervous system while many kids who develop it are still toddlers.
A research team led by the German Cancer Research Center in Heidelberg, Germany, has discovered that the genetic sequence of a tumor can be read like a molecular clock, traced back to its most recent common ancestor cell. ...
Researchers have identified new variations in neuroblastoma that could lead to a more accurate prognosis and better-targeted treatments for this devastating childhood cancer.
Apr 9, 2024
0
27
Neuroblastoma, one of the most common childhood cancers, is classified as a developmental cancer because it arises prenatally during the formation of organs and tissues. It originates from cancer cells that develop in neuroblasts, ...
Mar 28, 2024
0
8
The MYCN oncoprotein (proteins related to the growth of cancer cells) plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially in high-risk neuroblastoma ...
Mar 15, 2024
0
9
Chimeric antigen receptor (CAR)-T cell therapy is a potent emerging weapon against cancer, altering patients' T cells so they can better find and destroy tumor cells. But CAR-T cell therapy doesn't work well in every cancer—including ...
Mar 1, 2024
0
9
Injecting neuroblastoma tumors with Zika virus shrank or eliminated those tumors in studies with mice, suggesting that the virus could someday serve as an effective cancer therapy, according to a study led by Nemours Children's ...
Jan 9, 2024
0
37
A detailed 'atlas' of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for pediatric oncology in the Netherlands mapped this childhood tumor at the level of individual ...
Jan 4, 2024
0
67
In 2003, the first year of her fellowship in pediatric oncology, two of Giselle Saulnier Sholler's first three patients had died from neuroblastoma, closely matching the 30% survival rate expected at the time for high-risk ...
Dec 15, 2023
0
16
Children with neuroblastoma—responsible for 15% of cancer deaths in this age group—could in future be given treatments with fewer side-effects than those associated with the current chemotherapy, thanks to a discovery ...
Sep 20, 2023
0
43
Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 new cases per year in the US. Close to 50 percent of neuroblastoma cases occur in children younger than two years old. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system or SNS. It most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.
Neuroblastoma is one of the few human malignancies known to demonstrate spontaneous regression from an undifferentiated state to a completely benign cellular appearance.
A disease exhibiting extreme heterogeneity, neuroblastoma is stratified into three risk categories: low, intermediate, and high risk. Low-risk disease is most common in infants and highly curable with observation only or surgery, whereas high-risk disease is difficult to cure even with the most intensive multi-modal therapies available.
Note: Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. However, since it is not a sympathetic nervous system malignancy it is a distinct clinical entity and is not to be confused with neuroblastoma.
This text uses material from Wikipedia, licensed under CC BY-SA